Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Levesque

Physician Assistant, Medical Fall River, MA Physician Assistant

NPI 1487698908 CMS profile 11181667

775 Davol St, Fall River, MA 02720

Open in the dashboard

General payments

$14,656

721 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Levesque of Fall River, MA is reported in the CMS Open Payments database as having received $14,656 across 721 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,692 159
2024 General $3,490 167
2023 General $3,499 177
2022 General $2,332 123
2021 General $1,643 95

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Levesque
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jennifer Levesque were reported at $3,692. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jennifer Levesque Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,643 $156 $41–$563 $132
2022 $2,332 $185 $55–$649 $149
2023 $3,499 $199 $58–$717 $160
2024 $3,490 $206 $62–$740 $164
2025 $3,692 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $4,279 262 payments
  2. Janssen Biotech, Inc. $2,443 97 payments
  3. LEO Pharma Inc. $1,406 64 payments
  4. Pfizer Inc. $1,032 71 payments
  5. E.R. Squibb & Sons, L.L.C. $939 40 payments
  6. Regeneron Healthcare Solutions, Inc. $685 29 payments
  7. UCB, Inc. $674 23 payments
  8. Genzyme Corporation $508 31 payments
  9. Arcutis Biotherapeutics, Inc. $497 19 payments
  10. Lilly USA, LLC $452 20 payments
  11. Other $1,742 65 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,872 708 payments
  2. Education $784 13 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $2,110 76 payments
  2. SKYRIZI $2,010 123 payments
  3. RINVOQ $1,588 101 payments
  4. ADBRY $1,144 51 payments
  5. SIMPONI ARIA $988 50 payments
  6. STELARA $988 50 payments
  7. SIMPONI $988 50 payments
  8. SOTYKTU $912 39 payments
  9. DUPIXENT $823 41 payments
  10. CIBINQO $788 60 payments
  11. Other $6,642 335 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

716

Median for Physician Assistant: 241

Drug cost

$798,453

Median for Physician Assistant: $4,110

Branded share of claims

10.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 13 $258,763
Skyrizi Risankizumab-Rzaa Brand 12 $240,731
Tremfya Guselkumab Brand 14 $192,457
Dupixent Pen Dupilumab Brand 18 $67,257
Zoryve Roflumilast Brand 18 $15,460
Ivermectin Generic 25 $4,563
Fluorouracil Generic 70 $3,968
Fluocinolone Acetonide Generic 30 $2,193
Mometasone Furoate Generic 132 $1,901
Clobetasol Propionate Generic 21 $1,755

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$89,545

Medicare's payments for the services billed

Medicare patients

597

Average age 75

Services billed

2,502

383 women, 214 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 22%
Ischemic heart disease 21%
Chronic kidney disease 21%
Osteoporosis 21%
Atrial fibrillation 18%
Depression 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $558
$558 25 —
DUPIXENT
  • GENZYME CORPORATION $229
  • Regeneron Healthcare Solutions, Inc. $198
  • SANOFI-AVENTIS U.S. LLC $85
$512 18 —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $412
$412 — —
ADBRY
  • LEO Pharma Inc. $388
$388 — —
RINVOQ
  • AbbVie, Inc. $302
$302 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

721 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record